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The U.S. Food and Drug Administration (FDA) emphasizes drug product development by
Quality by Design (QbD). Critical material attributes (CMAs) are a QbD element that has an
impact on pharmaceutical operations and product quality. Pharmaceutical drugs often crystallize
as needle-shaped (a CMA) particles and affect the process due to poor flowability, low bulk
density, and high compressibility, and eventually the product performance. In this study, the
product obtained from crystallization was needle-shaped Ciprofloxacin HCl (CIPRO), formed
lumps during drying, and compacted during processing through feeders. To delump small
amounts of materials and break the needles, multiple available devices (mortar-pestle, Krups
grinder) and custom-made grinder were assessed before formulation. The processed CIPRO
powder was then used to make tablets in the miniature tablet manufacturing unit developed by
the team at MIT. The critical quality attributes (CQA) of the tablets, set by the United States
Pharmacopeia (USP), were then assessed for the drug powder processed with each of these
devices. Powder properties comparable to commercial CIPRO were obtained when the custom
MIT-designed grinder was used, leading to tablets that meet the USP criteria, with comparable
dissolution profiles of those for marketed CIPRO tablets. This study demonstrates how needle-
shaped crystals have an impact on pharmaceutical operations, even if it is on a miniature scale,
and how proper shape and subsequent flow properties can be obtained by processing the
particles through the MIT team-designed grinder.
KEY WORDS: critical material attributes (CMAs); needle-shaped particles; miniature pharmaceutical
unit operations; Ciprofloxacin HCl; direct compressible tablets.
INTRODUCTION
The U.S. Food and Drug Administration (FDA) encour-
ages the adoption of quality by design (QbD) principles in the
development and manufacturing of drug products (1). FDA
emphasizes quality must be built into the manufactured
product. QbD elements include the critical quality attributes
(CQAs) of the drug product, identification of critical material
attributes (CMAs) and critical process parameters (CPPs),
and linking CMAs and CPPs to CQAs (1). A CMA is a
physical, chemical, microbiological, or biological characteris-
tic or property of an input material that should be within an
acceptable range, limit, or distribution to ensure the antici-
pated quality of that in-process material, excipient, or drug
substance (1). CMAs can significantly impact pharmaceutical
unit operations, process consistency, and product quality
attributes (2). Hence, material properties need to be tested
and CMAs need to be defined and controlled.
Pharmaceutical drugs or active pharmaceutical ingredi-
ents (APIs) often crystallize as particles with high aspect
ratio, typically as needle-shaped particles or elongated plates
(3). This behavior has been reported for salicylic acid,
aliskiren hemifumarate, alisertib sodium, or melitracen hy-
drochloride, among others (4–7). Needle-shaped crystals, in
particular, are typified by aspect ratios in the range of (≈
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1:1:100−1000) (8). However, it is worth noting that crystals
with aspect ratios of (1:1:≳ 10) may still be “troublesome”
during processing operations (8). Drug substance’s physical
properties such as particle morphology (shape) have a
significant impact when designing and developing a robust
drug product having envisioned CQAs (1). The manifestation
of needle-shaped API is often considered high risk and a
source of difficulty (flowability tends to be minimized, which
in turn can negatively impact processing characteristics such
as hopper discharge, die filling, and other volumetric dosing
operations) in the manufacture of pharmaceutical dosage
forms (9). Drug particle shape can affect downstream
processability and cause physical characterization difficulties
and drug product performance issues such as a poor
dissolution rate or bioavailability (9, 10). Particle shape can
affect content and dose uniformity, the grittiness of solid
particles in chewable tablets, and other properties related to
physicochemical stability (11). Crystal shape and facet-specific
mechanical properties can affect the fracture cleavage behav-
ior of organic crystalline materials (12). Particles with less
spherical shape tend to have larger contact area due to more
uniform particle arrangements (13). This results in higher
compact strength. Particle cohesiveness, to some extent, is
desirable in the formulation process and for increased tablet
strength; however, increased particle cohesiveness can lead to
operational difficulties due to compaction of particles inside
the process (13). The buildup of compacted material leads to
an operational problem in constant uniform feeding.
In the pharmaceutical industry, opportunities to modify
existing processes are often limited due to regulatory and
safety requirements (8). Typically several strategies have
been considered to handle needle-shaped particle formation:
alteration to crystallization process using crystal habit mod-
ifying additives, manipulation of solvents, ultrasonication, and
mechanical operation (milling) are some examples (14). Each
approach has its drawbacks. For example, micronization via
dry milling yields an increase in the cohesiveness of particles
generates a risk for dust explosion, and it is unfeasible for
stress-sensitive compounds and crystal forms (14, 15). Crystal
habit modifying polymers can radically affect API solubility,
resulting in unacceptable yields. Hence, its concentration
must be controlled in the same way as any other impurity (9).
Solvent selection is also limited due to toxicity, impact on
environment, and yield (16). Given these limitations, milling
and micronization are still, at present, an attractive approach
routinely used to obtain consistent particle size and shape
modification during downstream formulation processing (9,
12).
At the Massachusetts Institute of Technology (MIT), we
developed a compact, portable, re-configurable, and auto-
mated system (Fig. 1) that offers the means for on-site, on-
demand manufacturing of pharmaceutical tablets from drug/
API crystals (17, 18). The system was designed to achieve
1000 drug doses per day for immediate or close-to-immediate
use. The system consists of the feeding of API and excipients,
blending, dispensing, and compression to make tablets. It
handles a few grams of materials as the number of doses is
small compared to commercial manufacturing. In this study,
we emphasize how particle shape, especially needle-shaped,
critical material attributes, impacted on different unit opera-
tions of the system, even at a small scale. We also discuss
different grinding options that were investigated to improve
the processability of needle-shaped particles. Finally, we
demonstrate that the grinder recently designed by the MIT
team (19, 20) performed well for small-scale powder, that the
powder can easily be processed through the system, and that
the manufactured oral dosage tablets showed a comparable
performance of the commercially marketed product.
MATERIALS AND METHODS
Materials
Ciprofloxacin hydrochloride monohydrate (CIPRO,
99.8% purity) was purchased from Jai Radhe Sales (Gujrat,
India) and used as the model drug. Bulk density, compres-
sion, biopharmaceutical properties, stability/target shelf life,
etc., determines the selection of excipients to design the drug
product. Stability improvement excipients were not consid-
ered as manufacturing is an on-demand basis. A simplified
method in formulation development was deliberated by
reducing the number of excipients necessary for tableting
(17, 21). Hence, to formulate only one filler/diluent, flow aid/
glidant, and lubricant were chosen. Silicified microcrystalline
cellulose (Prosolv SMCC® HD 90) was gifted by JRS Pharma
GMBH & CO. KG (Rosenberg, Germany) and considered as
the filler/diluent, fumed silica (CAB-O-SIL® M-5P) was
gifted by Cabot Corporation (MA, USA) and considered as
the Glidant, and Magnesium stearate (Kosher Passover
HyQual™), gifted by Mallinckrodt Pharmaceuticals (MO,
USA), was considered as the lubricant. Sodium starch
glycolate (EXPLOTAB®) gifted by JRS Pharma GMBH &
CO. KG (Rosenberg, Germany) was used as a disintegrant to
improve the disintegration of CIPRO tablets, as this process
yields a volume dosage form that requires a higher compac-
tion force than the reported earlier work with the drugs used
in the unit (17). SSG also improves subsequent dissolution
(22, 23). The materials considered in this study, along with
their particular roles and relevant physical properties, are
presented in Table I.
Crystallization and Mechanical Processing of CIPRO
The downstream process crystallized CIPRO as needle-
shaped particles, with an aspect ratio of approximately 1:1:20.
To obtain a similar particle shape from commercial material,
the commercial CIPRO was recrystallized following the
procedure that was intended for downstream manufacturing.
The crystallization feed solution was prepared by dissolving
100 mg/mL of commercial Ciprofloxacin HCl in 25 vol%
formic acid, 75 vol% water. Then, the API was recrystallized
through the addition of isopropanol as an antisolvent. This
was done in a continuous flow manner, as reported in
previous work (24). The final antisolvent content was 80
vol%, yielding a suspension with approximately 18 mg/mL of
crystalline API. Ultrasonication of the crystallized API was
considered as an alternative for particle breakage of the
needle-shaped crystals. For those tests, 150 mL of the
crystallization suspension was sonicated using a Hielscher
UP100H device (100 watts, 30 kHz) connected to an MS1
sonotrode, inserted directly into the sample. The sonication
time was kept at 10 min, using a constant amplitude of 100%.
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Both the crystallized suspension and the samples processed
by ultrasonication were filtered, washed with a 20 vol%
water, 80% acetone solution, and dried at 50°C at 0.5 bar in a
vacuum oven for 24 h. Industrial drying processes relying on
Nutsche filter dryers tend to produce a large amount of
lumps, even with agitated drying. Consequently, it is common
to implement delumping processes before formulation.
However, no suitable commercial equipment was found to
delump the small amount of powder that is generated in this
type of study. Hence, a mortar-pestle, a Krups grinder
(Figure S1), and a customized grinder (Fig. 2) designed at
MIT were used. The custom-built grinder is a compact device
designed for the integrated filtration, drying, and mechanical











Fig. 1. (a) Compact, portable, re-configurable, and automated tablet manufacturing unit [72.4 cm (length) × 53.3 cm (width) × 134.6 cm
(height)], volume 0.52 m3. (b) Schematic of the process for direct compression tablet manufacturing. (c) Feeder to feed API and excipients. (d)
Custom-designed tapping feeder to feed powder blend
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Capellades et al. (19) and a patent application (20). In this
study, the grinding experiments were conducted following the
procedure mentioned in Capellades et al. (19). After 65 min
of static drying, the powder was mechanically processed
through agitated drying for 55 min, with a constant impeller
rotation speed of 30 rpm. The powder properties are achieved
in the agitated drying step by utilizing an impeller geometry
that promotes delumping, controlling the distance between
the impeller blade and the bottom of the plate at 0.5 mm, and
using an impeller rotation program with direction switch as
described in Capellades et al. (19). The delumped CIPRO
was sieved using a 600-μm sieve (Figure S2) because the head
of the blend dispensing unit (tapping feeder) has an opening
hole of 700 μm. The obtained powder was then used for on-
demand tablet manufacturing in the compact system.
Physical Characterization of CIPRO, Excipients, and Blends
To develop and manufacture pharmaceutical formula-
tions as well as finished products, it is important to
characterize and understand API, excipients, and blend
properties at the particle and bulk level (25). Bulk density,
flow properties, size, and shape of CIPRO, excipients
(explicitly fillers), and blends were assessed to develop the
formulation. Scirocco 2000, dry powder dispersion unit of
Mastersizer 2000 particle size analyzer (Malvern Panalytical
Inc.), was used to measure the particle size of CIPRO and
excipients. API or excipients were placed in an enclosed
vibratory tray. Then, compressed air was used to suspend the
particles of the sample and pass through the air cell. To feed
the powder, a 50% feed rate setting was used in the vibratory
tray of Scirocco 2000. A 2 bar air pressure was used to
disperse the powder through the air cell. The Mastersizer
2000 provided volume-weighted particle sizes. The fumed
silica CAB-O-SIL® M-5P has a median size of about 14 nm
as reported elsewhere (26). Optical microscopy images of the
CIPRO powder were captured with a Nikon microscope
(Eclipse ME600) equipped with a Nikon DS-Ri1 camera.
FT4 Powder Rheometer (Freeman Technology, Tewkes-
bury, UK) was used to measure bulk density and powder flow
properties of CIPRO, excipients, and blends. In the FT4, the
bulk density test was done using conditioned bulk density test
and completed before any other test. Shear cell test was used
to measure powder flow property. Powder compressibility
was also measured. Bulk density is a key factor in determin-
ing the amount of powder that can fit in a space such as a
tablet press hopper, a tablet die, or a blender (25). Powder
flow measurements and a flow coefficient can be obtained
from the shear test. The flow function coefficient (ffc) is used
as an indicator of the powder flowability and is defined as the
ratio of the major principal stress to the unconfined yield
strength. The ffc has been acquired in this work using 3 kPa
of normal stress. Based on Schulze (27), ffc values can be
defined into different regimes: ffc < 1, not flowing; 1< ffc < 2,
very cohesive; 2 < ffc < 4, cohesive; 4 < ffc <10, easy flowing,
and ffc > 10, free-flowing. Powder compressibility (the
capability of powder to reduce in volume under pressure),
denoted as the percentage change in volume after compres-
sion, was also measured. Compressibility does not directly
measure the flowability; however, a free-flowing powder
generally has a low compressibility value. A compressibility
value of more than 30% specifies poor powder flow (28). The
detailed procedures of each FT4 Powder Rheometer test can
be found in the literature (29).
Manufacturing and Characterization of CIPRO Tablets
CIPRO tablets were manufactured in the unit using the
delumped and ground CIPRO powder. An 11-mm die and
punch (round-shaped) set was used. One thousand-kilogram
compression force was applied. Tablet properties such as
weight, content uniformity, assay, tensile strength, and
dissolution performance were evaluated. USP39-NF34 official
monographs were followed to do all characterization (30).
Tablet Weight and Tensile Strength
Tablet weight was determined in the weighing station
(custom-designed) fabricated on a Sartorius load cell (Sarto-
rius WZA 224-L). Tablet breaking force or hardness was
measured using the tablet hardness tester (Dr. Schleuniger
Pharmatron Model 6D). Tensile strength was calculated using
tablet hardness according to the relationship mentioned in
Table I. Materials Used for Making CIPRO Tablets and Their Properties
Name of ingredient Quantity Percentage
composition
((%) w/w)





mg d10 d50 d90
Ciprofloxacin
HCl (CIPRO)1
291.002 58.20 Active pharmaceutical
ingredient
- - - - - -
Silicified microcrystalline
cellulose
189.00 37.80 Diluent 38.83 127.61 324.56 0.52 6.17 >
10
Fumed silica 5.00 1.00 Glidant/flow aid - - - - - -
Magnesium stearate 5.00 1.00 Lubricant 2.76 6.86 15.10 0.31 38.97 5.18




2Amount reflects conversion from monohydrate salt form to the free base (250 mg)
3 Flow function coefficient
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Azad et al. (21). This tensile strength was measured for six
tablets and the average was reported.
Assay of Tablets
Assay of the CIPRO tablets was conducted using high-
performance liquid chromatography Ascentis® 25 cm ×
4.6 mm × 5 μm C8 column and an Agilent 1200 series
G1315D Diode Array Detector. For all the measurements,
the column temperature was maintained at 30 ± 1°C and the
detection wavelength at 278 nm. Ten microliters was injected
to the mobile phase flowing at a rate of 1.5 mL/min. The
mobile phase was set at a volumetric ratio of acetonitrile to
solution C of 13:87. Solution C was 0.025 M phosphoric acid,
adjusted with triethylamine to a final pH of 3.0 ± 0.1. The
sample solution was prepared using five tablets in solution B
using a 500-mL volumetric flask. The solution was filtered
through a 0.45-μm filter and diluted to prepare the equivalent
of the API concentration of 0.2 mg/mL. Solution B was
prepared at a volumetric ratio of acetonitrile to solution A of
13:87. Solution A was 0.025 M phosphoric acid, having a pH
of 2.0 ± 0.1 adjusted by triethylamine.
Tablet Content Uniformity Determination
To confirm consistency, each tablet in a manufactured
batch should have a drug substance content within 85–
115% of the labeled content which is measured as 100%.
Content uniformity or weight variation (USP-39 < 905 >
Uniformity of Dosage Units) is the method that is
considered to demonstrate uniformity (31). Uncoated
tablets having 25 mg or more drug substance comprising
25% or more, by weight of the tablet, required to follow
the weight variation method. The content uniformity
method needs to be followed where the weight variation
method does not meet the requirements. In this study,
CIPRO was tested by the weight variation method. Ten




















Fig. 2. (a) Schematic of the grinder designed at MIT. (b) Picture of the grinder
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described above. USP < 905 > Uniformity of Dosage
Units method was used to calculate acceptance value
(AV). AV of 15 or less should be expected to confirm
content uniformity.
Dissolution of Tablets
USP II paddle method using a Varian VK 7025
dissolution apparatus (Varian, Inc., USA) was used to
perform tablet dissolution. USP 39–NF 34 official monograph
was chosen to select the dissolution conditions. For CIPRO,
the dissolution medium volume was 900 mL 0.1 N hydrochlo-
ric acid. The rotational speed of the paddle was 50 rpm. The
temperature was kept at 37°C ± 0.2°C. In the beginning,
tablets were manually added to the dissolution media. The
UV was measured in an automatic Varian UV–Vis Cary 50
apparatus having the in situ probes set at 276 nm for CIPRO.
A total of three tablet’s dissolution was measured. The
average value with standard deviation was stated. The
dissolution was compared with commercially available
CIPRO tablets packaged by American Health Packaging
(Columbus, OH 43217).
RESULTS AND DISCUSSION
Particle Shape and Its Impact on Miniature Pharmaceutical
Unit Operations
Figure 1a shows the tablet manufacturing unit (17, 21)
and different miniature pharmaceutical unit operations such
as different feeders for API and excipients, blender, tapping
feeder for dispensing powder blend, tablet press, etc. Each
component is a plug-and-play type and easy to assemble and
disassemble. An enclosure was used for the solids module to
prevent airflow that may cause weighing cell fluctuation and
the transfer of dust powder (if any generates) to the
environment. Figure 1b shows the process flow diagram
(PFD), which represents the general flow of the process and
equipment. There are five volumetric feeders (Orbetron 50
series micro feeder, OD50SV) mounted in the feeder array.
In this study, four feeders were used. Each feeder consists of
feeder housing, disc (50 mm in diameter, 10 pockets open
hole), powder discharge chute having adafruit vibrating mini
motor disc, and hopper (Fig. 1c). To improve cohesive
powder flow, 18 g of 5-mm glass beads was added in the
feeder and SiO2 was premixed with the drug powder. The
beads help to enhance the powder flow by breaking the
powder’s compaction when the disc rotates. All feeders feed
the materials on the powder carrier, which transfers the
powder into the blender. The blended powder is then fed into
the tablet die using the custom-designed tapping feeder (Fig.
1d). The amount of materials used for blending is based on
the percentage composition given in Table I and the total
blend mass is 45.69 g.
Powder flow properties such as size, shape, and bulk
density impacted the feeder performance. Table I shows
material compositions that are used for making CIPRO
tablets and their flow properties. The crystallized CIPRO
was needle-shaped with a high aspect ratio (approximately
1:1:20) (Fig. 3a), and it was very fluffy. Hence, it is not
suitable to use through the unit and its flow properties were
not measured. Similarly, nano-silica, CAB-O-SIL® M-5P,
flow properties were not measured as it is very fluffy due to
its nano size, formed aggregates, and showed a lack of
consistency in flow behavior. The bulk density of CAB-O-
SIL® M-5P is < 0.06 g/cm3, reported by Cabot Corporation
(32). The low bulk density value confirms the observation of
fluffy behavior. Comparing the flow properties of all excipi-
ents, magnesium stearate has a finer particle size, low bulk
density, high compressibility, and low ffc. In general, when
particle size increases, powder flowability increases, a weaker
interparticle force between particles is observed, and the
cohesivity of the powder decreases (33). The powder bulk
density increases as powder pack in a denser state due to an
increase in particle size (33). Based on Schulze classification
(27), both Prosolv SMCC® and EXPLOTAB® are free-
flowing, whereas magnesium stearate flows easily. Hence, all
excipient powders were easily handled through the feeders.
As expected for elongated particles, the needle-shaped
CIPRO occupies a large volume per unit mass. Its bulk
density, as well as flow behavior, can be improved by reducing
its aspect ratio. At first, ultrasound was applied to the
crystallization suspension to attempt at breaking the needle-
shaped crystals. While some effect was observed, sonication
alone was unable to eliminate completely all particles’ needle
shapes (Fig. 3b). Since there was no sufficient improvement in
the crystals’ aspect ratio, CIPRO was now crystallized without
ultrasound and delumped-grounded using the Krups grinder
(Figure S1a, S2). The CIPRO premixed with CAB-O-SIL was
then processed through the Orbetron feeder. However, the
particles were not able to feed through the feeder after the
first 1 or 2 min. They formed a compact mass which
prevented the powder from flowing. Figure 4a shows the
feeder after the powder flow stops. Since silica premixed
CIPRO did not flow through the Orbetron feeder, it was
added into the blender manually. The powder blend was
prepared and dispensed into the tapping feeder. After a few
taps of dispensing, the blend’s powder flow stopped due to
the formation of a compact mass. Figure 4b shows the tapping
feeder after the powder flow stopped. The silica premixed
CIPRO powder and CIPRO blend behavior can be easily
correlated with the flow properties found in FT4 measure-
ments, as presented in Tables II and III. It is observed in
Table II that CIPRO (w/o US, Krups Grinder) has a low bulk
density (0.22 g/cm3) and ffc (1.26), and high compressibility
(52.6). Similarly, the CIPRO blend (Table III) has a low bulk
density and ffc, and high compressibility. Hence, CIPRO
powder and blend had a very poor flow behavior. The overall
findings show particle shape has an impact on pharmaceutical
unit operations even if it is on a miniature scale.
Processing of Needle-shaped CIPRO Particles
Only applying ultrasound during crystallization or using
Krups grinder for crystallized CIPRO did not help to break
the needle shape of CIPRO particles and subsequently
improve powder flow properties. Hence, the combined
process was applied. For this, ultrasound was applied during
crystallization, and the dried powder was subsequently
ground. CIPRO was ground using either Krups grinder or
mortar and pestle (Figure S1a, b). Mortar and pestle can
handle a small mass of materials and it can apply gentle shear.
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However, its operation is biased due to human handling, and
it is not efficient for handling a large amount of powder.
Krups grinder can handle a large amount of CIPRO but it
works at one speed. It also applies high stress compared to a
mortar and pestle. Both mortar and pestle and Krups grinder
helped delumping. The properties of CIPRO powder crystal-
lized using ultrasound and ground using Krups or mortar and
pestle are given in Table II. No appreciable difference in flow
properties was observed when comparing to CIPRO particles
ground with Krups grinder with those ground with a mortar
and pestle. The bulk density and compressibility were also in
the same range. The optical microscopy images of CIPRO
particles (Fig. 3c) show that very fine particles were produced
for the Krups grinder, whereas for mortar and pestle, the
particle size was slightly reduced (Fig. 3d). However, it was
not possible to eliminate the needle-shaped crystals
completely even after applying the combined process.
Comparing to Krups ground particles, mortar and pestle
ground particles have higher aspect ratios (see Fig. 3c, d).
This is due to low shear applied to particles by the mortar and
pestle. The comparison of powder blends of both types of
blend shows no significant difference in flow properties
(Table III).
The combined approach of ultrasonication and off-line
mechanical processing was not able to improve powder flow
properties. Therefore, the powder was not suitable for
dispensing and tableting. As an alternative approach, we
attempted to integrate the mechanical processing of the API
within the drying step in drug substance isolation. In this
context, we designed and developed a miniature unitfor
integrated filtration, drying, and mechanical processing of
APIs (19, 20). This unit would allow us to conduct necessary
drug substance isolation processes, and utilize a combination
of mechanical processing and in situ feedback control on the
Fig. 3. Optical microscopy image of Ciprofloxacin HCl (CIPRO) crystal particles: (a) downstream
process crystallized (w/o ultrasound) needle-shaped CIPRO; (b) crystalized w/ ultrasound; (c)
crystallized w/ ultrasound and ground w/ Krups grinder; (d) crystallized w/ ultrasound and ground
w/ mortar and pestle; (e) crystalized w/o ultrasound and ground w/ MIT-designed grinder; and (f)
commercially available and un-processed
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API dry matter content to eliminate the needle-like crystals
during the drying process. Figure 2 (a, b) shows a schematic
and the grinder itself, respectively. CIPRO powder produced
using the MIT-designed device shows a high bulk density
(0.48) and ffc (4.17), and low compressibility (29.5). The
desirable ffc value is greater than 4 and a compressibility
value of less than 30% (27). Comparing all processed
powders, it has better powder flow properties (see Table II),
and it does not require the addition of off-line mechanical
processing between drug substance isolation and formulation.
It is also noted that the CIPRO used for the MIT grinder was
crystallized without any ultrasound applied in the down-
stream process. The particle size d50 and d90 are larger for the
MIT-designed grinder compared to other processed particles.
The particle size (specifically d50:14.45 vs 12.49 μm) and flow
properties are similar to the commercial CIPRO powder
manufactured in bulk and purchased from the market.
Commercial CIPRO powder did not require any processing,
and it flows very well through the tablet manufacturing unit in
Fig. 1. The particle shape was observed in optical microscopy
and shown in Fig. 3e. There were no more long needle-
shaped particles detected. Instead, a combination of fine and
large particles was observed with aspect ratios around or
below 1:1:2, similar to what is observed for commercially
processed CIPRO. The particle shape of commercially
processed CIPRO is shown in Fig. 3f. This corroborates the
particle size distribution presented in Table II. The powder
blend was also prepared and characterized by FT4. Results
show that the blend properties were significantly improved
for the CIPRO processed in the MIT-designed device. The
silica premixed CIPRO powder and CIPRO blend were
processed through the Orbetron feeder and tapping feeder.
There were no issues observed. Both the powder and blend
flowed well.
CIPRO Tablet Manufacturing and Performance Evaluation
To make directly compressible tablets, the powder
should have good flow properties, be readily compressed,
and have a high bulk density. Large variability in tablet
weight, poor content uniformity, and inconsistent tablet
properties such as breaking force, dissolution, and disintegra-
tion can occur if the powder has poor flow (34). Powder blend
produced using CIPRO from the MIT-designed grinder shows
good flow properties, so tablets were manufactured using the
miniature manufacturing unit. Figure 5 shows a picture of
those tablets. Following the intended dosage of 250 mg of
CIPRO, tablets are embossed with the text “CIP 250”. Ten
(a) (b)
Fig. 4. Processing issues observed due to needle-shaped CIPRO. Hard compacts formed
during (a) CIPRO (premix with SiO2) feeding through Orbetron feeder and (b) CIPRO
blend feeding through tapping feeder
Table II. Properties of Processed CIPRO Particles




Flow function coefficient (ffc)
d10 d50 d90
CIPRO (w/o US*, Krups grinder) 1.23 3.88 33.26 0.22 52.6 1.26
CIPRO (US and Krups grinder) 1.93 7.09 65.36 0.38 38.8 1.56
CIPRO (US and mortar-pestle) 3.01 8.67 24.02 0.41 43.6 2.04
CIPRO (w/o US, grinder designed at MIT) 2.82 14.45 169.73 0.48 29.5 4.17
CIPRO (commercially
available, un-processed)
3.75 12.49 439.56 0.39 38.9 2.95
*US: ultrasound applied during crystallization
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tablets average weight with %RSD, as presented in Table IV,
was 479 mg, and the weight variation was within 10% of the
target weight. The RSD value is 5%, which indicates a
uniform blend is being dispensed into the die, and the tablets
manufactured in the unit have low weight variations. The
average diameter, thickness, and tensile strength of six tablets
are 11.08 mm, 3.88 mm, and 4.67 MPa, respectively. A small
increase in the tablet diameter was observed as a result of
gradual radial recovery during ejection. Seton et al. (35)
reported an observation of gradual radial recovery of tablets.
Tensile strength is an essential quality attribute that impacts
post compaction process operations such as dissolution,
coating, storage, and handling. The tablet strength depends
on the formulation composition and compression force
applied. In this work, the maximum compression force
1000 kg was applied by the tablet press.
According to the USP-39 official monograph, tablets
meet the assay standard when tablets are between 90 and
110% of the labeled amount of API. In the same way, the
tablet meets the USP quality standard if the calculated
acceptance value of CIPRO is less than or equal to 15.0,
based on 10 dosage units. It is observed from Table IV that
the assay value of CIPRO tablets is within the range,
90~100%, and that it meets content uniformity/weight
variation criteria since the acceptance value (AV) is lower
than 15. Figure 6 shows the evolution of the dissolution of
CIPRO tablets after manufacturing and compared with
commercially available tablets in a USP II apparatus.
According to the USP monograph, 85% of the CIPRO
should dissolve within 30 min. The CIPRO tablets meet the
USP monograph. The faster dissolution of CIPRO tablets
implies instant release tablets, caused by a faster disintegra-
tion due to the presence of super disintegrant SSG. The







CIPRO (w/o US*, Krups grinder) 0.44 32.5 2.06
CIPRO (US & Krups grinder) 0.55 23.0 2.41
CIPRO (US & mortar-pestle) 0.51 23.2 4.67
CIPRO (w/o US, grinder designed at MIT) 0.57 12.4 >10
CIPRO (commercial, un-processed) 0.69 21.1 8.25
*US ultrasound applied during crystallization
Fig. 5. Picture of CIPRO tablets produced
Table IV. Properties of Tablets (Weight, Tensile Strength, Assay, and Acceptance Value) Prepared Using Blends
Blends Tablet weight (Average, %
RSD) (mg)
Tensile strength (average ±
STDEV) (MPa)
Assay (% of the labeled
content) (%)
A c c e p t a n c e
value (AV)
CIPRO (w/o US, grinder
designed at MIT)
479.0, 5.0 4.67 ± 0.09 97.42 12.95
RSD: Relative Standard Deviation, STDEV: Standard Deviation
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dissolution profile is comparable to the profile for commercial
tablets. Initially, the commercial tablets have slow-release
compare to MIT-manufactured tablets that may be due to the
coating of the commercial tablets.
CONCLUSIONS
Particle shape can impact powder flow behavior. Phar-
maceutical unit operations are sensitive to particle shape,
especially for systems presenting high aspect ratios. Grinding
is very well-known in the pharmaceutical industry. However,
to handle a small amount of powder, there is no miniature
equipment available commercially. At MIT, we designed a
grinder integrated with a filter dryer that produces dry
CIPRO powder with optimum flow properties which are
suitable for tableting. The tablet properties meet USP criteria
and the dissolution profile is comparable to commercial
CIPRO tablets. The overall findings, comparing this system
to common alternatives, demonstrate that needle shape has
an impact on pharmaceutical processing even on a miniature
scale. These challenges have been overcome by the MIT-
designed grinder.
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